ArticleRMD open2021
Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.
Article in RMD open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 3 syntheses or guidelines pooled it, 169 citations in OpenAlex.
- Rheumatoid Arthritis and COVID-19 at the Intersection of Immunology and Infectious Diseases: A Related PRISMA Systematic Literature Review.International journal of molecular sciences · 2024Pooled it
- Risk of flare or relapse in patients with immune-mediated diseases following SARS-CoV-2 vaccination: a systematic review and meta-analysis.European journal of medical research · 2024Pooled it
- Guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force.Advances in rheumatology (London, England) · 2022Guideline
- Safety of CoronaVac and ChAdOx1 vaccines against SARS-CoV-2 in patients with rheumatoid arthritis: data from the Brazilian multicentric study safer.Advances in rheumatology (London, England) · 2024Trial
- Understanding caregiver vaccine hesitancy and experiences in children with paediatric rheumatic diseases: results from the C19-GRA Global Pediatric Survey.EULAR rheumatology open · 2026Article
- Primary and Booster COVID-19 Vaccination in Patients with Sjögren's Disease: Data from the Longitudinal SAFER Cohort Study.Vaccines · 2025Article
- Flares of Systemic Autoimmune Rheumatic Disease Following Coronavirus Disease 2019 Vaccination: A Narrative Review.Rheumatic diseases clinics of North America · 2025Review
- Long-term antibody responses to COVAXIN and COVISHIELD vaccines in rheumatoid arthritis patients and healthy control population - A cross-sectional study.Journal of family medicine and primary care · 2025Article
- COVID-19 vaccination-related delayed adverse events among people with rheumatoid arthritis: results from the international COVAD survey.Rheumatology international · 2024Article
- Infection-Associated Flares in Systemic Lupus Erythematosus.Pathogens (Basel, Switzerland) · 2024Article
- Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry.Annals of the rheumatic diseases · 2024Article
- Safety of COVID-19 Vaccination in Patients with Rheumatic and Musculoskeletal Diseases: A Cross-sectional Study in Egypt.Oman medical journal · 2024Article
- Safety of COVID-19 Vaccine in Patients with Rheumatic and Musculoskeletal Diseases.Mediterranean journal of rheumatology · 2024Article
- Analysis of related factors for RA flares after SARS-CoV-2 infection: a retrospective study from patient survey.Scientific reports · 2024Article
- COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group.Rheumatology international · 2024Article
- Correlates of breakthrough COVID-19 in vaccinated patients with systemic sclerosis: survival analysis from a multicentre international patient-reported survey.Rheumatology international · 2024Article
- Real-world data on tolerability of COVID-19 vaccination in patients with rheumatoid arthritis based on patient-reported outcomes.Rheumatology advances in practice · 2024Article
- Autoimmune rheumatic diseases and COVID-19 vaccination: a retrospective cross-sectional study from Astana.Reumatologia · 2024Article
- Knowledge and practices of vaccination for children with rheumatic diseases: A single-center study in China.Human vaccines & immunotherapeutics · 2023Article
- Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
50 authors at 20 institutions in 15 countries.
Funding
Abstract
backgroundWe describe the early experiences of adults with systemic rheumatic disease who received the COVID-19 vaccine.
methodsFrom 2 April to 30 April 2021, we conducted an online, international survey of adults with systemic rheumatic disease who received COVID-19 vaccination. We collected patient-reported data on clinician communication, beliefs and intent about discontinuing disease-modifying antirheumatic drugs (DMARDs) around the time of vaccination, and patient-reported adverse events after vaccination.
resultsWe analysed 2860 adults with systemic rheumatic diseases who received COVID-19 vaccination (mean age 55.3 years, 86.7% female, 86.3% white). Types of COVID-19 vaccines were Pfizer-BioNTech (53.2%), Oxford/AstraZeneca (22.6%), Moderna (21.3%), Janssen/Johnson & Johnson (1.7%) and others (1.2%). The most common rheumatic disease was rheumatoid arthritis (42.3%), and 81.2% of respondents were on a DMARD. The majority (81.9%) reported communicating with clinicians about vaccination. Most (66.9%) were willing to temporarily discontinue DMARDs to improve vaccine efficacy, although many (44.3%) were concerned about rheumatic disease flares. After vaccination, the most reported patient-reported adverse events were fatigue/somnolence (33.4%), headache (27.7%), muscle/joint pains (22.8%) and fever/chills (19.9%). Rheumatic disease flares that required medication changes occurred in 4.6%.
conclusionAmong adults with systemic rheumatic disease who received COVID-19 vaccination, patient-reported adverse events were typical of those reported in the general population. Most patients were willing to temporarily discontinue DMARDs to improve vaccine efficacy. The relatively low frequency of rheumatic disease flare requiring medications was reassuring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.